Literature DB >> 34609662

Prevalence, clinical features, risk factors, and outcomes of SLE patients with aortic aneurysm: a cross-sectional retrospective study in a Chinese single center.

Ju Zhang1, Jie Gao1, Ruina Kong1, Chenxin Cheng2, Qian Chen1, Yunxia Xia1, Xiaofang Li1, Ti Zhang3, Qing Cai4.   

Abstract

OBJECTIVES: The prevalence, clinical features, and outcomes of patients with systemic lupus erythematosus (SLE) complicated with or without aortic aneurysm (AA) were compared in a Chinese single-center cohort.
METHODS: Included in this study were SLE patients who received treatment at Shanghai Changhai Hospital between 2000 and 2020. The prevalence, clinical features, and outcomes of these SLE patients with or without AA were compared by Student's t-tests or Fisher's exact tests as appropriate. Risk factors associated with AA occurrence in SLE were evaluated by univariable and multivariable logistic regression analyses. The survival analysis between SLE patients with or without AA was conducted by the Kaplan-Meier method.
RESULTS: Of the 1843 SLE patients included in this study, 16 (0.86%) were identified as having AA, and 160 of the remaining 1825 SLE patients without AA were selected as a simple random sample for comparison. The SLE patients with AA showed a higher proportion of smoking and hypertension as compared with those with no AA. Multivariable logistic regression analysis showed that a long SLE duration and anti-RNP positivity were two independent risk factors associated with AA occurrence in SLE patients. The log rank test showed that SLE patients with AA had a significantly higher risk of progression to death. Renal disorder was associated with an even poorer outcome in SLE patients with AA.
CONCLUSION: The incidence of AA in SLE patients may be underestimated. The association between AA and SLE, especially in patients with multiple risk factors, should not be ignored. Key Points • The risk of SLE patients developing AA may be higher than that previously estimated. • The risk of SLE patients especially with multiple risk factors developing AA should not be ignored. • The diagnosis of AA should not be forgot when SLE patients present with chest, back, or abdominal symptoms with unexplained causes.
© 2021. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Anti-RNP antibody; Aortic aneurysm; Systemic lupus erythematosus (SLE)

Mesh:

Year:  2021        PMID: 34609662     DOI: 10.1007/s10067-021-05927-w

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  6 in total

1.  Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors.

Authors:  Murray B Urowitz; Dominique Ibañez; Dafna D Gladman
Journal:  J Rheumatol       Date:  2006-11-15       Impact factor: 4.666

2.  Accurately describing changes in disease activity in Systemic Lupus Erythematosus.

Authors:  D D Gladman; M B Urowitz; A Kagal; D Hallett
Journal:  J Rheumatol       Date:  2000-02       Impact factor: 4.666

3.  Framingham, ACC/AHA or QRISK3: which is the best in systemic lupus erythematosus cardiovascular risk estimation?

Authors:  Marco Di Battista; Chiara Tani; Elena Elefante; Davide Chimera; Linda Carli; Francesco Ferro; Chiara Stagnaro; Marta Mosca
Journal:  Clin Exp Rheumatol       Date:  2019-10-28       Impact factor: 4.473

4.  Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity.

Authors:  R J Cook; D D Gladman; D Pericak; M B Urowitz
Journal:  J Rheumatol       Date:  2000-08       Impact factor: 4.666

5.  Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study.

Authors:  M Petri; M Genovese; E Engle; M Hochberg
Journal:  Arthritis Rheum       Date:  1991-08

6.  Chronobiological patterns of acute aortic dissection in central China.

Authors:  Liangtao Xia; Lu Huang; Xin Feng; Jiewen Xiao; Xiang Wei; Xinyu Yu
Journal:  Heart       Date:  2020-07-13       Impact factor: 5.994

  6 in total
  2 in total

Review 1.  Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.

Authors:  Stefan Schreiber; Shomron Ben-Horin; Rieke Alten; René Westhovens; Laurent Peyrin-Biroulet; Silvio Danese; Toshifumi Hibi; Ken Takeuchi; Fernando Magro; Yoorim An; Dong-Hyeon Kim; SangWook Yoon; Walter Reinisch
Journal:  Adv Ther       Date:  2022-01-06       Impact factor: 4.070

2.  A Prospective Follow-Up Study on the Disease Course and Predictors of Poor Outcomes in a Random Population-Based Cohort of Newly Diagnosed Lupus Patients.

Authors:  Saadat Ullah; Muhammad Haroon; Farzana Hashmi; Zaid Tayyab; Saba Javed
Journal:  Cureus       Date:  2022-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.